- Clone:
- REA1521 | B2M-01
- Type of antibody:
- Recombinant antibodies, Primary antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for ß2 Microglobulin Antibody, anti-human, REAfinity™
Clone REA1521 recognizes β2-Microglobulin (B2M), which is the soluble light chain of the MHC class I complex and is essential for its correct folding, transport, and surface expression on cells. Beyond its role in antigen presentation, it also participates in immune regulation and affects cell growth, survival, migration, angiogenesis, and even metastasis in cancer cells. β2-Microglobulin is present on all nucleated cells, but not expressed in red blood cells, as these lack MHC class I complexes. As a soluble protein, it circulates in the serum, urine, and other bodily fluids and is thus found throughout the body.
Serum and urinary levels of B2M are used to assess glomerular filtration rate and to differentiate between glomerular and tubular kidney diseases.
β2-Microglobulin is a prognostic marker in hematologic malignancies. Elevated B2M levels correlate with tumor burden and prognosis in diseases such as multiple myeloma, chronic lymphocytic leukemia (CLL), and lymphomas. It is a component of staging systems like the International Staging System (ISS) in myeloma. Overexpression of B2M promotes tumor growth, migration, and invasion across various cancer types. It also acts as a signaling molecule and is being investigated as a potential therapeutic target.
Additional information: Clone REA1521 displays negligible binding to Fc receptors.
Beta-2-microglobulin, B2M, beta2 Microglobulin
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?